Cuba's Abdala Vaccine to Begin Phase III of Clinical Trials
The Center for Genetic Engineering and Biotechnology will guarantee the doses needed for this clinical trial in which 42,000 people will take part. | Read More
The Center for Genetic Engineering and Biotechnology will guarantee the doses needed for this clinical trial in which 42,000 people will take part. | Read More